<- Go Home

Kezar Life Sciences, Inc.

Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States.

Market Cap

$54.1M

Volume

69.6K

Cash and Equivalents

$34.9M

EBITDA

-$94.9M

Tax Rate Collected

N/A

Tax Rate Ratio

N/A

Gross Profit

-$72.4M

Profit Margin

N/A

52 Week High

$11.35

52 Week Low

$5.20

Dividend

N/A

Price / Book Value

0.40

Price / Earnings

-0.56

Price / Tangible Book Value

0.40

Enterprise Value

-$77.4M

Enterprise Value / EBITDA

0.86

Operating Income

-$96.0M

Return on Equity

-54.72%

Return on Assets

-29.02

Cash and Short Term Investments

$148.4M

Debt

$16.9M

Equity

$134.0M

Revenue

N/A

Unlevered FCF

-$42.3M

Sector

Biotechnology

Category

N/A

Company Stock Pitches